Tiragolumab with atezolizumab for previously untreated non-small cell lung cancer

Tiragolumab with atezolizumab is currently in development for patients with previously untreated locally advanced unresectable or metastatic programmed death-ligand 1 (PD-L1) selected non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK. Metastatic (or advanced) NSCLC is when the cancer has spread beyond the lung that was initially affected, most often to the liver, adrenal glands, bones, and the brain. Most patients with NSCLC are diagnosed at the advanced/metastatic stage where curative treatment with surgery is unsuitable.